



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54

(51) Int Cl.:
C07D 231/54 ^(2006.01) **C07D 401/12** ^(2006.01)
A61K 31/416 ^(2006.01) **A61K 31/435** ^(2006.01)
A61P 3/10 ^(2006.01) **A61P 9/00** ^(2006.01)
A61P 13/00 ^(2006.01)

(48) Corrigendum issued on:
04.05.2016 Bulletin 2016/18

(86) International application number:
PCT/EP2009/052660

(45) Date of publication and mention
of the grant of the patent:
24.02.2016 Bulletin 2016/08

(87) International publication number:
WO 2009/109654 (11.09.2009 Gazette 2009/37)

(21) Application number: **09718101.0**

(22) Date of filing: **06.03.2009**

(54) **1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE
TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1 AND CX3CR1**

1-BENZYL-3-HYDROXYMETHYLINDAZOLDERIVATE UND IHRE VERWENDUNG BEI DER
BEHANDLUNG VON AUF DER EXPRESSION VON MCP-1 UND CX3CR1 BASIERTEN
ERKRANKUNGEN

DÉRIVÉS DE 1-BENZYL-3-HYDROXYMETHYLINDAZOLE ET UTILISATION ASSOCIÉE DANS LE
TRAITEMENT DES MALADIES BASÉ SUR L'EXPRESSION DE MCP-1 ET CX3CR1

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK TR**

- **FURLOTTI, Guido**
I-00151 Roma (IT)
- **MANGANO, Giorgina**
I-00139 Roma (IT)
- **CAZZOLLA, Nicola**
I-00041 Albano Laziale (roma) (IT)

(30) Priority: **07.03.2008 EP 08425141**

(43) Date of publication of application:
22.12.2010 Bulletin 2010/51

(74) Representative: **Allaix, Roberto**
Marchi & Partners S.r.l.
Via Vittor Pisani, 13
20124 Milano (IT)

(73) Proprietor: **Aziende Chimiche Riunite Angelini**
Francesco A.C.R.A.F. S.p.A.
00181 Roma (IT)

(56) References cited:
WO-A-99/04770 US-A1- 2006 047 126
US-A1- 2007 043 057

(72) Inventors:
• **GUGLIELMOTTI, Angelo**
I-00149 Roma (IT)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).